POINT Biopharma
POINT Biopharma developed radioactive medicines that home in on prostate cancer and neuroendocrine tumours, and built a large manufacturing campus in Indianapolis. Eli Lilly bought the company at the end of 2023.
Overview
POINT Biopharma Global Inc. (formerly Nasdaq: PNT) was an Indianapolis radiopharmaceutical company with late-stage radioligand therapies: PNT2002, a PSMA-targeted therapy for metastatic castration-resistant prostate cancer after progression on hormonal treatment, and PNT2003, a somatostatin receptor (SSTR)-targeted therapy for gastroenteropancreatic neuroendocrine tumours, both partnered with Lantheus outside certain Asian territories, plus earlier clinical and preclinical programmes. It operated a 180,000 square foot radiopharmaceutical manufacturing campus in Indianapolis and an R&D centre in Toronto. On 2 October 2023 Eli Lilly agreed to acquire POINT through a cash tender offer of USD 12.50 per share, and the merger was completed in late December 2023; the company website now redirects to lilly.com.
Scorecard
All companies- phase 3 +3
- targets +2
- modalities +2
- registry trials +4
Funding
All companiesInvestors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · Cash tender offer at USD 12.50 per share, an aggregate of approximately USD 1.4 billion, under a merger agreement dated 2 October 2023; completion reported in an 8-K filed 27 December 2023 | 2023 | $1.4B | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
A radioactive drug that homes in on a marker found on most prostate cancer cells, delivering radiation directly to the tumour, is being tested as a treatment for prostate cancer that has stopped responding to hormone therapy.
Notes
top- pointbiopharma.com redirects to lilly.com, recorded as the website. Deal value and pipeline details come from the Lilly press release filed as exhibit 99.4 to POINT's 8-K of 3 October 2023.
Similar pages
not linked directly; found by shared links- TechnologyRadioligand plus DNA-repair inhibitor combinations
Shares Somatostatin receptor 2, PSMA, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- InstitutionIRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)
Shares Somatostatin receptor 2, PSMA, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- PersonSimron Singh
Shares Somatostatin receptor 2, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- InstitutionInselspital, Bern University Hospital / University Cancer Center Inselspital
Shares Somatostatin receptor 2, PSMA, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- PersonEmily K. Bergsland
Shares Somatostatin receptor 2, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- CompanyARTBIO
Shares PSMA, Radioligand therapy (beta emitters), Prostate cancer.
- InstitutionUppsala University Hospital / Uppsala University
Shares Somatostatin receptor 2, Neuroendocrine tumours, Radioligand therapy (beta emitters), Prostate cancer.
- TrialSPLASH
Shares Lutetium-177 PNT2002, Prostate cancer.